Treatment of Osteoporosis in Men

a Department of Endocrinology and Unit for Osteoporosis and Metabolic Bone Diseases, Ghent University Hospital, De pintelaan 185, B9000 Gent, Belgium b Head Bone and Cartilage Metabolism Unit, CHU Centre-Ville, Liège, Belgium c Division of Gerontology and Geriatrics and Centre for Musculoskeletal Research, Department of Experimental Medicine, Leuven University, Leuven, Belgium d Unit of Metabolic Bone Diseases, Department of Internal Medicine, University of Florence, Florence, Italy e MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK f NIHR Musculoskeletal Biomedical Research Unit, Institute of Musculoskeletal Sciences, University of Oxford, Oxford, UK g Amgen, Uxbridge, UK h Arthritis Unit UCL5390, Université Catholique de Louvain, B-1200 Brussels, Belgium i Hospital del Mar-IMIM-Universitat Autónoma, Barcelona, Spain j Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Sheffield, UK k Academic Unit of Bone Metabolism, University of Sheffield and NIHR Musculoskeletal Biomedical Research Unit, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK l Lilly Research Labs, Eli Lilly and Company, Indianapolis, USA m Bone and Mineral Unit, Department of Medicine, Oregon Health & Sciences University, Portland, OR, USA n West-German Osteoporosis Center (WOZ) at Klinikum Leverkusen, University of Cologne, Germany o Department of Endocrinology, CHU de Nancy, Vandoeuvre, France p Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, 1211 Geneva 14, Switzerland